Citi forecasts Novo Nordisk Wegovy sales ahead of Q3

0842 GMT - Novo Nordisk third-quarter sales could come in just above consensus after the strong Wegovy pill launch in the U.K., Citi analysts write. The bank forecasts sales 1% ahead of consensus, with sales of the Wegovy pill posting a 16% beat, while adjusted operating income is likely to land only in line, due to higher research and development costs which will weigh on margins. While Citi expects a Wegovy pill beat would be welcome, it still sees poor visibility on injectable Wegovy pricing and growing long-term competition threats from Eli Lilly, Roche, Pfizer and AstraZeneca as likely to keep many investors on the sidelines. The bank lowers its target price to 296 Danish kroner from 310 kroner and keeps its neutral rating. Shares rise 1.3% to 253.15 kroner. (dominic.chopping@wsj.com) (END) Dow Jones Newswires October 09, 2026 04:42 ET (08:42 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.